Clinical Research of Pulse-activating Injection Combined with Chemotherapy on Gastric Cancer in Medium-advanced Stage, A Report of 33 Cases
Hao Shulan, Liu Likun, Wang Xixing, Li Jin, Li Yifang. Clinical Research of Pulse-activating Injection Combined with Chemotherapy on Gastric Cancer in Medium-advanced Stage, A Report of 33 Cases. Shaan Xi Zhong Yi. 2013, 29 (2): 9-11.
To observe the effect of Shengmai Injection combined with chemotherapy on gastric cancer in medium to advanced stages, 67 patients with gastric cancer in medium to advanced stage were randomly divided into two groups, 33 cases in treatment group and 34 cases in control group. The therapeutic regimen selected DOF, and the treatment group was treated with Shengmai Injection as well, 40 mL a day. One treatment course included 21 days, and after 2 treatment courses the results were observed. After 2 courses of treatment the effective rate of treatment group was 66.67% (95% CI=50.59% -82.75 %) on tumor size changes, and the effective rate of control group was 41.18% (95% CI=24.64% -57.72%). There was a significant difference between the two groups on the integrated effect (u=2.507 7, P=0.012 7). The rate of chemo- therapy completion was 96.97% (95 % CI=83.68 % -99.90%) in treatment group, and 76.47% (95% CI=62.21% -90.73%). There was significant difference between the two groups (X2=4.327 6, P<0.05). As well as with the Kanorfsky animation score (u=2.7033, P=0.008 4) and syndrome evaluation (u=2.375 9, P=0.018 0). Shengmai Injection combined with chemotherapy has better effect on gastric cancer in medium to advanced stage than single chemotherapy alone. It has a reliable effect on tumor mass (OR=0.35, 95% CI=0.13 - 0.94, NNT=4, 95% CI=2.03 - 62.11), but the benefits in regards to the rate of chemotherapy completion and Kanorfsky animation score is not definite (OR and 95% CI are over 1).
Systematic Review of Shengmai Injection for Cardiotoxicity Induced by Anthracyclines
Yang Min, Lu Jing, Mou Jin-jin, Xu Ting. Systematic Review of Shengmai Injection for Cardiotoxicity Induced by Anthracyclines. Zhong Guo Yao Wu Jing Jie. 2012, 9 (11): 666-669.
To explore the effect of Shengmai injection on cardiotoxicity in tumor patients induced by anthracyclines we systematically retrieved the randomized controlled trials (RCTs) which were designed for Shengmai injection for cardiotoxicity in tumor patients induced by anthracyclines. The three researchers selected the references according to the inclusion criterion, then appraised them critically and conducted meta-analysis. Six RCTs were included at last with 615 patients, 307 in the experimental group and 308 in the control group. The two groups have statistically significant differences in every outcome we have designed: rate of abnormal electrocardiogram [RR=0.38, 95%CI (0.27, 0.54), P<0.00001], change of EF[MD=-2.50, 95%CI (-3.83, -1.18), P=0.0002], change of LVDd [MD=-0.79, 95%CI (-0.93, -0.66), P<0.00001], change of LVDs[MD=-0.58, 95%CI (-0.82, -0.35), P<0.00001], change of FS[MD=-3.02, 95%CI (-5.02, -1.01), P=0.003]. Conclusion On current evidence, Shengmai injection is probably effective for the prevention and treatment of cardiotoxicity in tumor patients induced by anthracyclines. However, more high quality clinical trials are needed to confirm this.